LXRX
NASDAQ · Pharmaceuticals
Lexicon Pharmaceuticals Inc
$2.31
+0.09 (+4.05%)
Financial Highlights (FY 2026)
Revenue
63.80M
Net Income
-64,498,006
Gross Margin
99.4%
Profit Margin
-101.1%
Rev Growth
+692.7%
D/E Ratio
0.50
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 99.4% | 55.1% | 55.1% | 55.1% |
| Operating Margin | -98.2% | 30.4% | 28.2% | 31.7% |
| Profit Margin | -101.1% | 28.4% | 29.0% | 33.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 63.80M | 68.34M | 62.90M | 66.37M |
| Gross Profit | 63.45M | 37.63M | 34.64M | 36.55M |
| Operating Income | -62,658,450 | 20.76M | 17.72M | 21.02M |
| Net Income | -64,498,006 | 19.40M | 18.23M | 21.89M |
| Gross Margin | 99.4% | 55.1% | 55.1% | 55.1% |
| Operating Margin | -98.2% | 30.4% | 28.2% | 31.7% |
| Profit Margin | -101.1% | 28.4% | 29.0% | 33.0% |
| Rev Growth | +692.7% | +10.7% | +9.3% | +0.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 149.24M | 183.67M | 161.72M | 163.58M |
| Total Equity | 297.18M | 200.03M | 220.65M | 240.93M |
| D/E Ratio | 0.50 | 0.92 | 0.73 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -61,847,403 | 29.54M | 28.34M | 30.60M |
| Free Cash Flow | — | 10.65M | 12.86M | 11.69M |